ANIXA BIOSCIENCES, INC. (ANIX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31..
Quick ratio
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.75M USD | Liabilities, Current |
| Cash and equivalents | 1.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | (m) | $1.75M | $1.40M | (m) | (m) | (m) | (m) |
| 2026-04-30 | (m) | $1.50M | $1.48M | (m) | (m) | (m) | (m) |
| 2026-01-31 | (m) | $1.24M | $1.55M | (m) | (m) | (m) | (m) |
| 2025-10-31 | (m) | $1.97M | $1.24M | (m) | (m) | (m) | (m) |
| 2025-07-31 | (m) | $2.07M | $1.50M | (m) | (m) | (m) | (m) |
| 2025-04-30 | (m) | $1.89M | $1.91M | (m) | (m) | (m) | (m) |
| 2025-01-31 | (m) | $2.00M | $1.05M | (m) | (m) | (m) | (m) |
| 2024-10-31 | (m) | $2.50M | $1.27M | (m) | (m) | (m) | (m) |
| 2024-07-31 | (m) | $2.00M | $1.23M | (m) | (m) | (m) | (m) |
| 2024-04-30 | (m) | $1.68M | $995.00K | (m) | (m) | (m) | (m) |
| 2024-01-31 | (m) | $1.66M | $998.00K | (m) | (m) | (m) | (m) |
| 2023-10-31 | (m) | $2.03M | $915.00K | (m) | (m) | (m) | (m) |
| 2023-07-31 | (m) | $1.86M | $3.20M | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | $1.54M | $5.62M | (m) | (m) | (m) | (m) |
| 2023-01-31 | (m) | $1.23M | $9.79M | (m) | (m) | (m) | (m) |
| 2022-10-31 | (m) | $2.04M | $12.36M | (m) | (m) | (m) | (m) |
| 2022-07-31 | (m) | $1.47M | $24.25M | (m) | (m) | (m) | (m) |
| 2022-04-30 | (m) | $1.19M | $27.73M | (m) | (m) | (m) | (m) |
| 2022-01-31 | (m) | $1.79M | $29.78M | (m) | (m) | (m) | (m) |
| 2021-10-31 | (m) | $1.27M | $29.13M | (m) | (m) | (m) | (m) |
| 2021-07-31 | (m) | $1.21M | $27.22M | (m) | (m) | (m) | (m) |
| 2021-04-30 | (m) | $1.44M | $27.70M | (m) | (m) | (m) | (m) |
| 2021-01-31 | (m) | $1.53M | $11.98M | (m) | (m) | (m) | (m) |
| 2020-10-31 | (m) | $1.19M | $6.42M | (m) | (m) | (m) | (m) |
| 2020-07-31 | (m) | $1.21M | $5.93M | (m) | (m) | (m) | (m) |
| 2020-04-30 | (m) | $1.08M | $2.89M | (m) | (m) | (m) | (m) |
| 2020-01-31 | (m) | $1.13M | $2.82M | (m) | (m) | (m) | (m) |
| 2019-10-31 | (m) | $1.48M | $3.49M | (m) | (m) | (m) | (m) |
| 2019-07-31 | (m) | $1.44M | $4.40M | (m) | (m) | (m) | (m) |
| 2019-04-30 | (m) | $1.60M | $3.82M | (m) | (m) | (m) | (m) |
| 2019-01-31 | (m) | $1.33M | $4.15M | (m) | (m) | (m) | (m) |
| 2018-10-31 | (m) | $1.27M | $3.06M | (m) | (m) | (m) | (m) |
| 2018-07-31 | (m) | $1.13M | $2.59M | (m) | (m) | (m) | (m) |
| 2018-04-30 | (m) | $1.34M | $4.17M | (m) | (m) | (m) | (m) |
| 2018-01-31 | (m) | $1.09M | $2.85M | (m) | (m) | (m) | (m) |
| 2017-10-31 | (m) | $889.49K | $3.34M | (m) | (m) | (m) | (m) |
| 2017-07-31 | (m) | $2.93M | $1.83M | (m) | $221.05K | (m) | (m) |
| 2017-04-30 | (m) | $3.66M | $2.88M | (m) | (m) | (m) | (m) |
| 2017-01-31 | (m) | $3.72M | $1.40M | (m) | (m) | (m) | (m) |
| 2016-10-31 | (m) | $468.76K | $2.49M | (m) | (m) | (m) | (m) |
| 2016-07-31 | (m) | $531.62K | $2.05M | (m) | (m) | (m) | (m) |
| 2016-04-30 | (m) | $706.93K | $2.61M | (m) | (m) | (m) | (m) |
| 2016-01-31 | (m) | $1.24M | $3.98M | (m) | (m) | (m) | (m) |
| 2015-10-31 | (m) | $593.78K | $4.37M | (m) | (m) | (m) | (m) |
| 2015-07-31 | (m) | $711.67K | $5.16M | (m) | (m) | (m) | (m) |
| 2015-04-30 | (m) | $688.68K | $6.08M | (m) | (m) | (m) | (m) |
| 2015-01-31 | (m) | $1.67M | $7.81M | (m) | $45.00K | (m) | (m) |
| 2014-10-31 | (m) | $1.81M | $3.36M | (m) | $400.00K | (m) | (m) |
| 2014-07-31 | (m) | $8.36M | $3.65M | (m) | $133.33K | (m) | (m) |
| 2014-04-30 | (m) | $10.68M | $617.72K | (m) | $828.37K | (m) | (m) |
| 2014-01-31 | (m) | $11.55M | $776.14K | (m) | (m) | (m) | (m) |
| 2013-10-31 | (m) | $3.21M | $898.17K | (m) | $175.00K | (m) | (m) |
| 2013-07-31 | (m) | $3.09M | $982.03K | (m) | (m) | (m) | (m) |
| 2013-04-30 | (m) | $3.30M | $1.27M | (m) | (m) | (m) | (m) |
| 2013-01-31 | (m) | $3.44M | $1.71M | (m) | (m) | (m) | (m) |
| 2012-10-31 | (m) | $1.82M | $339.69K | (m) | $7.00K | (m) | (m) |
| 2012-07-31 | (m) | $1.78M | $101.53K | (m) | (m) | (m) | (m) |
| 2012-04-30 | (m) | $2.13M | $130.73K | (m) | (m) | (m) | (m) |
| 2012-01-31 | (m) | $2.06M | $463.04K | (m) | (m) | (m) | (m) |
| 2011-10-31 | (m) | $2.11M | $774.04K | (m) | (m) | (m) | (m) |
| 2011-07-31 | (m) | $2.93M | $551.40K | (m) | (m) | $33.36K | (m) |
| 2011-04-30 | (m) | (m) | $347.10K | (m) | (m) | (m) | (m) |
| 2011-01-31 | (m) | (m) | $978.96K | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | $450.12K | $1.09M | (m) | (m) | $51.97K | (m) |
| 2010-07-31 | (m) | (m) | $1.41M | (m) | (m) | (m) | (m) |
| 2009-10-31 | (m) | (m) | $1.45M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |